Abstract
Vaccines are an essential component in the fight against highly virulent respiratory pathogens such as influenza virus, Bordetella pertussis, and SARS-CoV-2. Although most existing vaccines for respiratory pathogens are injectable, development of efficacious intranasal vaccine formulations is a clear goal for the immunological community, especially as a result of the SARS-CoV-2 pandemic.1 Beyond the logistical benefits of needle-free vaccination,2 intranasal vaccines aim to induce mucosal immune responses in addition to systemic immunity, providing an additional layer of protection at the vulnerable respiratory interface.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
